BlueCrest Capital Management’s Sage Therapeutics SAGE Stock Holding History

BlueCrest Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,665	Closed	-$255K	–	1343
2018 Q4	$255K	Sell	2,665 -20,789	-89%	-$2.38M	0.01%	575
2018 Q3	$3.31M	Sell	23,454 -44,194	-65%	-$6.82M	0.09%	157
2018 Q2	$10.6M	Buy	67,648 +65,501	+3,051%	+$10.3M	0.27%	67
2018 Q1	$346K	Buy	+2,147	New	+$365K	0.01%	965
2017 Q2	–	Sell	-2,881	Closed	-$205K	–	1065
2017 Q1	$205K	Buy	+2,881	New	+$169K	0.01%	618

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlueCrest Capital Management's SAGE Position: Q1 2019 in Review

BlueCrest Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 2,665 shares — an estimated $255K sold.

BlueCrest Capital Management first reported a position in SAGE in Q1 2017 and held it in 5 quarters. The position peaked at $10.6M in Q2 2018. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

BlueCrest Capital Management reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
BlueCrest Capital Management sold 2,665 Sage Therapeutics shares in Q1 2019, an estimated $255K.
BlueCrest Capital Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 5 quarters.
BlueCrest Capital Management's Sage Therapeutics position peaked at $10.6M in Q2 2018.
268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on BlueCrest Capital Management's 13F filing for Q1 2019, filed 15 May 2019.